Canada markets open in 2 hours 49 minutes

Quest PharmaTech Inc. (QPT.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.0950-0.0100 (-9.52%)
At close: 3:55PM EDT
Full screen
Previous Close0.1050
Open0.1100
Bid0.0950 x 0
Ask0.1000 x 0
Day's Range0.0950 - 0.1100
52 Week Range0.0950 - 0.3200
Volume122,300
Avg. Volume42,060
Market Cap15.936M
Beta (5Y Monthly)1.43
PE Ratio (TTM)0.15
EPS (TTM)0.6550
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJul. 21, 2005
1y Target EstN/A
  • Quest Provides Update to Immunotherapy Asset Transfer Between OncoQuest Inc. and OncoQuest Pharmaceuticals Inc.
    CNW Group

    Quest Provides Update to Immunotherapy Asset Transfer Between OncoQuest Inc. and OncoQuest Pharmaceuticals Inc.

    Quest PharmaTech Inc. (TSXV: QPT) ("Quest") wishes to provide a further update regarding the final payment to be made pursuant to the Immunotherapy Asset Transfer between 45% owned OncoQuest Inc. ("OncoQuest") and OncoQuest Pharmaceuticals, Inc. (formerly Dual Industrial Co., Ltd.) (KOSDAQ: 078590 or 078590.KQ) ("OQP"). A second closing of the transaction has now occurred at which time all legal title and registrations for OncoQuest's immunotherapy assets were transferred to OQP. Under the terms of the transaction, the second closing entitled OncoQuest to receive the final payment of 65,229,709 shares of OQP with an ascribed value in the transaction of USD$175 million, subject to all required regulatory approvals. Although OncoQuest and OQP management continue to work diligently, Korean regulatory approval for the share payment has been further delayed and still has not been received. The delay relates to the audited financial statements for its most recently completed financial year. This delay has also resulted in trading in the shares of OQP on the KOSDAQ Exchange being halted effective March 24, 2021. It remains uncertain at this time as to whether regulatory approval will ultimately be received or the timing of any such approval.

  • CNW Group

    Quest Provides Corporate Update

    EDMONTON, AB , June 4, 2020 /CNW/ - Quest PharmaTech Inc. (QPT.V) ("Quest" or the "Company") wishes to provide a corporate update following the entering into of the asset transfer transaction between 40% owned OncoQuest Inc. ("OncoQuest") and Korean publicly traded Dual Industrial Co., Ltd.(078590.KQ) ('Dual") and the first closing under that transaction. A second closing of the transaction will occur upon completion of all transfers of legal title and registrations for OncoQuest's immunotherapy assets to Dual, which is expected to occur no later than December 31, 2020 . A minimum of US$62.5 million of these bonds may be redeemed for cash not later than December 31, 2020 and would be used by OncoQuest, in part, to pay for the costs of the transaction, including income taxes.